GORASP2

Across TCGA pan-cancer cohorts, GORASP2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GORASP2 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GORASP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GORASP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where GORASP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.253	0.730	<.001	67	view →
PDAC	DFS	Tertile	II,III,IV	0.498	0.135	.002	66	view →
LUAD	DFS	Quartile	II,III,IV	0.722	0.981	.002	10	view →
UCEC	DFS	Median	All	0.944	0.764	.003	8	view →
GBM	DFS	Quartile	All	0.590	0.843	.017	7	view →
COAD	DFS	Quartile	II,III,IV	1.000	0.902	.046	6	view →
LSCC	DFS	Median	II,III,IV	0.541	0.795	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GORASP2–CCRCC (DFS)

Open the CCRCC breakdown →